LogicBio Therapeutics ($LOGC)

Stock Image

LOGC Overview

LogicBio Therapeutics, a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform.The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company's lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth.It has a partnership with Children's Medical Research Institute to develop new viral vectors; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop new genome editing candidate LB-301 for the treatment of crigler-najjar syndrome.The company was founded in 2014 and is headquartered in Lexington, Massachusetts. (From: StockAnalysis.com)

MORE ABOUT LogicBio Therapeutics

Stay up to date with the best of Bullish each week.


Stay up to date with the best of Bullish each week.